Wetherby Asset Management Has Decreased Its Glaxosmithkline Plc (GSK) Stake, Derma Sciences (DSCI)’s Sentiment Is 0.71

June 20, 2017 - By Migdalia James

Derma Sciences, Inc. is a medical device company. The company has market cap of $197.88 million. The Firm operates through two divisions: advanced wound care and traditional wound care products. It currently has negative earnings. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.

Wetherby Asset Management Inc decreased Glaxosmithkline Plc (GSK) stake by 39.3% reported in 2016Q4 SEC filing. Wetherby Asset Management Inc sold 10,267 shares as Glaxosmithkline Plc (GSK)’s stock rose 5.47%. The Wetherby Asset Management Inc holds 15,860 shares with $611,000 value, down from 26,127 last quarter. Glaxosmithkline Plc now has $106.01B valuation. The stock declined 0.38% or $0.16 reaching $43.62 per share. About 116,153 shares traded. GlaxoSmithKline plc (ADR) (NYSE:GSK) has risen 4.26% since June 20, 2016 and is uptrending. It has underperformed by 12.44% the S&P500.

Analysts await GlaxoSmithKline plc (ADR) (NYSE:GSK) to report earnings on July, 26. They expect $0.71 EPS, up 1.43% or $0.01 from last year’s $0.7 per share. GSK’s profit will be $1.73B for 15.36 P/E if the $0.71 EPS becomes a reality. After $0.62 actual EPS reported by GlaxoSmithKline plc (ADR) for the previous quarter, Wall Street now forecasts 14.52% EPS growth.

Among 13 analysts covering GlaxoSmithKline (NYSE:GSK), 7 have Buy rating, 0 Sell and 6 Hold. Therefore 54% are positive. GlaxoSmithKline had 20 analyst reports since September 8, 2015 according to SRatingsIntel. JP Morgan maintained the shares of GSK in report on Wednesday, April 26 with “Neutral” rating. The rating was upgraded by Bryan Garnier & Cie on Wednesday, January 27 to “Buy”. As per Friday, February 26, the company rating was initiated by Cantor Fitzgerald. The stock has “Buy” rating by Jefferies on Thursday, July 14. The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) earned “Overweight” rating by Piperjaffray on Friday, September 23. BNP Paribas downgraded GlaxoSmithKline plc (ADR) (NYSE:GSK) on Wednesday, September 14 to “Underperform” rating. The stock has “Neutral” rating by Bank of America on Tuesday, September 8. J P Morgan Chase Co maintained the stock with “Neutral” rating in Friday, June 16 report. JP Morgan upgraded the shares of GSK in report on Monday, October 12 to “Neutral” rating. The firm earned “Neutral” rating on Tuesday, October 20 by Credit Suisse.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: